The use of intravenous immunoglobulin in Miller Fisher syndrome

Brain Dev. 1993 May-Jun;15(3):231-3. doi: 10.1016/0387-7604(93)90071-f.

Abstract

We report a patient with Miller Fisher syndrome who was treated with an intravenous high-dose of immunoglobulin. This syndrome is considered to be a benign variety of acute inflammatory demyelinating polyneuropathy (Guillain-Barré syndrome). However, there have been several reports of the need for ventilatory support and a few cases have had a fatal outcome. We observed a case of progressive Miller Fisher syndrome in a 3-year-old boy. Following 2 episodes of apnea lasting about 50 s each, he was treated with intravenous immunoglobulin (400 mg/kg/day) for 5 consecutive days. His respiratory state, general muscle strength, truncal ataxia and emotional state improved remarkably after this therapy.

Publication types

  • Case Reports

MeSH terms

  • Ataxia / therapy*
  • Child, Preschool
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use*
  • Male
  • Ophthalmoplegia / therapy*
  • Polyradiculoneuropathy / therapy*
  • Reflex
  • Syndrome

Substances

  • Immunoglobulins, Intravenous